Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO
New Delhi, Nov. 17 -- The candidate vaccine developed by the Oxford University and the Serum Institute of India is among the two such vaccines added to the ongoing Ebola clinical trials, according to a World Health Organisation (WHO) statement, making it the first addition of candidate vaccines to the trials specifically targeting the Bundibugyo virus that has caused the current Ebola outbreak in the Democratic Republic of the Congo.
"Expert groups convened by the WHO have recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo. The recommendation marks the first time vaccines specifically designed to protect against Bundibugyo virus, the virus responsible for the current outbreak, will be evaluated during an outbreak of the disease," said WHO. The two vaccine candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. htc...
To read the full article or to get the complete feed from this publication, please
Contact Us.